How LL-37 and Other Antimicrobial Peptides Bridge Innate and Adaptive Immunity in Psoriasis
Antimicrobial peptides (LL-37, defensins, S100 proteins, lipocalin 2, RNase 7) are overexpressed in psoriatic skin and link innate and adaptive immune responses driving disease progression.
Quick Facts
What This Study Found
LL-37, defensins, S100 proteins, lipocalin 2, and RNase 7 are highly expressed in psoriatic skin and bridge innate and adaptive immune responses in disease pathogenesis.
Key Numbers
LL-37, hBD1-4, S100 proteins, lipocalin 2, RNase 7 all highly expressed in psoriatic lesions
How They Did This
Narrative review of recent literature on AMPs in psoriasis, focusing on immunomodulatory mechanisms linking innate and adaptive immunity.
Why This Research Matters
Understanding how AMPs drive psoriasis — rather than just defend against infection — could lead to targeted therapies that modulate specific AMP functions without compromising antimicrobial defense.
The Bigger Picture
LL-37's role in psoriasis (activating dendritic cells via DNA complexes) was a landmark discovery. This review integrates newer findings showing that multiple AMP classes cooperate in driving psoriatic inflammation.
What This Study Doesn't Tell Us
Narrative review — no systematic search methodology; mostly mechanistic data from in vitro and animal studies; clinical implications of AMP-targeting therapies largely speculative.
Questions This Raises
- ?Could selectively blocking LL-37's immunomodulatory function (while preserving antimicrobial activity) treat psoriasis?
- ?Which AMP is the most critical driver of psoriasis — LL-37, defensins, or S100 proteins?
- ?Do AMP-targeting therapies risk increasing infection susceptibility?
Trust & Context
- Key Stat:
- 5 AMP classes LL-37, β-defensins, S100 proteins, lipocalin 2, and RNase 7 all overexpressed and immunomodulatory in psoriasis
- Evidence Grade:
- Moderate — well-supported review of established findings in psoriasis AMP biology.
- Study Age:
- Published in 2020; AMP roles in autoimmune skin disease continue to be refined.
- Original Title:
- Antimicrobial peptides: bridging innate and adaptive immunity in the pathogenesis of psoriasis.
- Published In:
- Chinese medical journal, 133(24), 2966-2975 (2020)
- Authors:
- Ma, Jing-Yi, Shao, Shuai, Wang, Gang(2)
- Database ID:
- RPEP-04977
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Why do protective peptides cause psoriasis?
In psoriasis, AMPs are overproduced and start activating immune cells beyond their antimicrobial role — forming complexes with DNA and activating dendritic cells that drive the inflammatory T cell response.
Is LL-37 the main culprit?
LL-37 was the first AMP linked to psoriasis (via DNA complexes activating dendritic cells), but this review shows defensins, S100 proteins, and others also play important bridging roles.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-04977APA
Ma, Jing-Yi; Shao, Shuai; Wang, Gang. (2020). Antimicrobial peptides: bridging innate and adaptive immunity in the pathogenesis of psoriasis.. Chinese medical journal, 133(24), 2966-2975. https://doi.org/10.1097/CM9.0000000000001240
MLA
Ma, Jing-Yi, et al. "Antimicrobial peptides: bridging innate and adaptive immunity in the pathogenesis of psoriasis.." Chinese medical journal, 2020. https://doi.org/10.1097/CM9.0000000000001240
RethinkPeptides
RethinkPeptides Research Database. "Antimicrobial peptides: bridging innate and adaptive immunit..." RPEP-04977. Retrieved from https://rethinkpeptides.com/research/ma-2020-antimicrobial-peptides-bridging-innate
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.